5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors

A method of treating a disease or disorder mediated by increased AKT protein kinase activity comprising administering to a mammal having said disease or disorder an effective amount of a compound of formula I to inhibit activity of an AKT protein kinase:

• or a stereoisomer or pharmaceutically acceptable salt thereof, wherein:
• R1 and R1a are independently selected from hydrogen, methyl, ethyl, —CH═CH2, —CH2OH, CF3, CHF2 or CH2F;
• R2 is selected from hydrogen, OH, OCH3 or F;
• R2a is selected from hydrogen, methyl or F, or
• R2 and R2a are oxo;
• L is selected from:
• wherein the single wavy line is where L attaches to A and the double wavy line is where L attaches to the pyrimidine;
• A is:
• X is a direct bond from L to Y, CH2, O, C═O, NH or C(═O)NH;
• Y is CH or N;
• Z is absent, CH2 or O, wherein L, X, Y, Z and b are selected so that any nitrogen is not bonded directly to another nitrogen;
• G is phenyl optionally substituted with one to four Ra groups or a 5-6 membered heteroaryl optionally substituted by a halogen;
• R3 and R4 are independently selected from hydrogen or methyl;
• R5 and R6 are independently selected from hydrogen or C1-C4 alkyl;
• a is 0 or 1;
• b is 0, 1 or 2;
• and
• each Ra is independently halogen, C1-C6-alkyl, C3-C6-cycloalkyl, —O—(C1-C6-alkyl), CF3, —OCF3, S(C1-C6-alkyl), CN, —OCH2-phenyl, NH2, —NO2, —NH—(C1-C6-alkyl), —N—(C1-C6-alkyl)2, piperidine, pyrrolidine, CH2F, CHF2, —OCH2F, —OCHF2, —OH, —SO2(C1-C6-alkyl), C(O)NH2, C(O)NH(C1-C6-alkyl), and C(O)N(C1-C6-alkyl)2;
• or
• b is 1, R3 is hydrogen and R4 and R5 together with the atoms to which they are attached form an optionally substituted 5-6 membered heterocyclic ring having one ring nitrogen atom, and R6 is selected from the group consisting of H or C1-C4 alkyl optionally substituted with OH or O(C1-C3 alkyl), such that A has the structure:
• Rc and Rd are independently selected from hydrogen and methyl;
• and
• c is 1 or 2;
• or
• b is 1, Z is CH2 and R5 and Y together with the atoms to which they are attached form an optionally substituted 6 membered heterocyclic ring having one ring nitrogen atom, and R6 is selected from the group consisting of hydrogen or C1-C4 alkyl optionally substituted with OH or O(C1-C3 alkyl), such that A has the structure: